Literature DB >> 7845043

Sarcoidosis.

R A DeRemee1.   

Abstract

Sarcoidosis is a systemic granulomatous process of unknown cause. Pathologically, it is characterized by noncaseous granuloma, and in more than 90% of patients, the lung or intrathoracic lymph nodes are affected. A roentgenographic staging system (stages I, II, and III), based on the appearance of the plain chest roentgenogram, conveys important information about prognosis, degree of symptoms, and pulmonary function abnormalities. The diagnosis should be confirmed by histopathologic examination and exclusion of known causes for the noncaseous granulomatous reaction. When indicated, treatment with alternate-day regimens of prednisone is highly effective. Serial chest roentgenography, pulmonary function studies, and the serum angiotensin-converting enzyme level are useful for monitoring the course of the disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7845043     DOI: 10.4065/70.2.177

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  6 in total

Review 1.  TAP deficiency syndrome.

Authors:  S D Gadola; H T Moins-Teisserenc; J Trowsdale; W L Gross; V Cerundolo
Journal:  Clin Exp Immunol       Date:  2000-08       Impact factor: 4.330

2.  Hair loss and plaquelike skin lesions.

Authors:  J C Cather; M A Menter
Journal:  Proc (Bayl Univ Med Cent)       Date:  2001-01

Review 3.  Sarcoidosis.

Authors:  D G Peckham; M A Spiteri
Journal:  Postgrad Med J       Date:  1996-04       Impact factor: 2.401

Review 4.  Cutaneous sarcoidosis.

Authors:  N J Wilson; C M King
Journal:  Postgrad Med J       Date:  1998-11       Impact factor: 2.401

5.  Medium term results of lung transplantation for end stage pulmonary sarcoidosis.

Authors:  S Walker; G Mikhail; N Banner; J Partridge; A Khaghani; M Burke; M Yacoub
Journal:  Thorax       Date:  1998-04       Impact factor: 9.139

Review 6.  Pulmonary hypertension associated with sarcoidosis.

Authors:  Robert P Baughman
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.